Maro Ohanian

Trials

Studies that name Maro Ohanian as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:54 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06811233 · Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

  M.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia (AML) · principal investigator
• Ph1
  NCT03630991 · Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  M.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · principal investigator
• Ph2
  NCT03589729 · Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

  M.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells · principal investigator
• Ph2
  NCT03136146 · Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  M.D. Anderson Cancer Center · recruiting · Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia · principal investigator
• Ph1/Ph2
  NCT02923986 · Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

  Bio-Path Holdings, Inc. · withdrawn · Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT02781883 · Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

  Bio-Path Holdings, Inc. · recruiting · Acute Myeloid Leukemia (AML) · principal investigator
• Ph1
  NCT01159028 · Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

  Bio-Path Holdings, Inc. · completed · Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Experimental Medicine Program
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026
  Named on NCT03589729